P526 Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients

Debbie S. Deben, A Van Bodegraven(Zuyderland Medisch Centrum), Marieke Pierik(Maastricht University Medical Centre), Paul Bus(Laurentius Ziekenhuis), Rob H. Creemers(Zuyderland Medisch Centrum), Dennis R. Wong(Zuyderland Medisch Centrum), Björn Winkens(Centraal Bureau voor de Statistiek), Nanne K.H. de Boer, Murat Şimşek, F Van Moorsel(Jeroen Bosch Ziekenhuis)
Journal of Crohn s and Colitis
January 1, 2022
10.1093/ecco-jcc/jjab232.653
Cited by 0

Related Papers

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
|The Lancet|2022|301
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252
Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease
|Gastroenterology|2015|199
Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts
|Inflammatory Bowel Diseases|2010|199
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
|Journal of Crohn s and Colitis|2019|183